Navigation Links
Nutraceutical Reports 2008 Fiscal Year End Results
Date:11/20/2008

2,235 4,202 18,960 20,923 Provision for income taxes 708 1,597 7,017 7,951 Net income $1,527 $2,605 $11,943 $12,972 Net income per common share Basic $0.14 $0.23 $1.09 $1.17 Diluted 0.14 0.23 1.07 1.15 Weighted average common shares outstanding Basic 10,846,018 11,136,702 10,993,505 11,054,828 Diluted 10,966,785 11,307,910 11,127,634 11,253,283 NUTRACEUTICAL INTERNATIONAL CORPORATION ADJUSTED EBITDA SCHEDULE (unaudited; dollars in thousands) Three months Twelve months ended ended September 30, September 30, 2008 2007 2008 2007 Net income $1,527 $2,605 $11,943 $12,972 Provision for income taxes 708 1,597 7,017 7,951 Interest and other (income)/expense, net (1) 262 443 1,270 1,257 Depreciation and amortization 1,603 1,292 5,859 4,793 Impairment of goodwill and intangible asset (2) 2,875 450 2,875 450 Adjusted EBITDA $6,975 $6,387 $28,964 $27,423 (1) Includes amortization of deferred financing fees. (2) A non-cash goodwill impairment charge of $2,875 related to the company's health food stores was recorded for the three months and twelve months ended September 30, 2008. A non-cash intangible asset impairment charge of $450 related to the re-b
'/>"/>
SOURCE Nutraceutical International Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Valensa and Parry Nutraceuticals Introduce Organic SpiruZan(TM) Spirulina/Astaxanthin Complex as Lifestyle Support for a Fast-Paced World
2. Nutraceutical to Present at Canaccord Adams Healthy Living Conference
3. Nutraceuticals could prevent diabetes
4. Nutraceutical Reports Q3 Results
5. Dermatologists In Denial: Controversial New Chocolate Nutraceutical Claims to be Good for Your Skin
6. Photos: For the First Time Researchers Show Reversal of an Aging Marker in the Human Retina Correlated with Visual Improvement Using a Nutraceutical Matrix (Longevinex(R))
7. Berkeley Premium Nutraceuticals Pushes Forward
8. Direct Response TV Course on Nutraceutical/Cosmeceutical Products to Premiere in New York City
9. Nellson Nutraceutical Names New Directors and Interim Chief Executive Officer
10. Nutraceutical Reports Fiscal 2008 Q1 Results
11. Neurochem appoints Mr. Gary Schmid as CEO of new nutraceutical business
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:Senators Lugar, Dodd, Boxer and Representatives Lee and McCollum Receive GAC Children's Champion Award 2Health News:Study shows surgery provides good long-term outcomes for patients with gastrointestinal cancers 2Health News:Medtronic, Inc. and Medtronic Sofamor Danek USA, Inc. Sued for Product Liability and Promoting the Off-Label Use of Infuse(R) Bone Graft Product, According to Page Perry, LLC 2Health News:Environmental Tectonics Corporation Announces Third Quarter and Year To Date Fiscal 2009 Results 2Health News:Environmental Tectonics Corporation Announces Third Quarter and Year To Date Fiscal 2009 Results 3Health News:Environmental Tectonics Corporation Announces Third Quarter and Year To Date Fiscal 2009 Results 4Health News:Environmental Tectonics Corporation Announces Third Quarter and Year To Date Fiscal 2009 Results 5Health News:Environmental Tectonics Corporation Announces Third Quarter and Year To Date Fiscal 2009 Results 6Health News:Environmental Tectonics Corporation Announces Third Quarter and Year To Date Fiscal 2009 Results 7Health News:Environmental Tectonics Corporation Announces Third Quarter and Year To Date Fiscal 2009 Results 8Health News:Environmental Tectonics Corporation Announces Third Quarter and Year To Date Fiscal 2009 Results 9Health News:Environmental Tectonics Corporation Announces Third Quarter and Year To Date Fiscal 2009 Results 10Health News:Most support Alzheimer's research based on family consent 2Health News:Most support Alzheimer's research based on family consent 3Health News:Physical activity, mood and serious mental illness 2
Breaking Medicine Technology:SRI International Receives National Institutes of Health Grants to Develop Improved Tomographic Imaging Technology 2SRI International Receives National Institutes of Health Grants to Develop Improved Tomographic Imaging Technology 3NOVAVAX Announces Closing of Public Offering of 6,800,000 Shares of Common Stock 2Sangart, Inc. Initiates Phase IIa Study of Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients With Hemorrhagic Shock 2Sangart, Inc. Initiates Phase IIa Study of Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients With Hemorrhagic Shock 3Living in U S May Raise Hispanics Cancer Risk 53835 1Living in U S May Raise Hispanics Cancer Risk 53835 2Living in U S May Raise Hispanics Cancer Risk 53835 3Angiotech Pharmaceuticals Inc announces financial results for the second quarter ended June 30 2009 13411 1Angiotech Pharmaceuticals Inc announces financial results for the second quarter ended June 30 2009 13411 2Angiotech Pharmaceuticals Inc announces financial results for the second quarter ended June 30 2009 13411 3Angiotech Pharmaceuticals Inc announces financial results for the second quarter ended June 30 2009 13411 4Angiotech Pharmaceuticals Inc announces financial results for the second quarter ended June 30 2009 13411 5Angiotech Pharmaceuticals Inc announces financial results for the second quarter ended June 30 2009 13411 6Angiotech Pharmaceuticals Inc announces financial results for the second quarter ended June 30 2009 13411 7Angiotech Pharmaceuticals Inc announces financial results for the second quarter ended June 30 2009 13411 8Angiotech Pharmaceuticals Inc announces financial results for the second quarter ended June 30 2009 13411 9Angiotech Pharmaceuticals Inc announces financial results for the second quarter ended June 30 2009 13411 10Angiotech Pharmaceuticals Inc announces financial results for the second quarter ended June 30 2009 13411 11Angiotech Pharmaceuticals Inc announces financial results for the second quarter ended June 30 2009 13411 12Angiotech Pharmaceuticals Inc announces financial results for the second quarter ended June 30 2009 13411 13Angiotech Pharmaceuticals Inc announces financial results for the second quarter ended June 30 2009 13411 14Angiotech Pharmaceuticals Inc announces financial results for the second quarter ended June 30 2009 13411 15Angiotech Pharmaceuticals Inc announces financial results for the second quarter ended June 30 2009 13411 16Angiotech Pharmaceuticals Inc announces financial results for the second quarter ended June 30 2009 13411 17Angiotech Pharmaceuticals Inc announces financial results for the second quarter ended June 30 2009 13411 18Angiotech Pharmaceuticals Inc announces financial results for the second quarter ended June 30 2009 13411 19Angiotech Pharmaceuticals Inc announces financial results for the second quarter ended June 30 2009 13411 20Angiotech Pharmaceuticals Inc announces financial results for the second quarter ended June 30 2009 13411 21Angiotech Pharmaceuticals Inc announces financial results for the second quarter ended June 30 2009 13411 22Angiotech Pharmaceuticals Inc announces financial results for the second quarter ended June 30 2009 13411 23Angiotech Pharmaceuticals Inc announces financial results for the second quarter ended June 30 2009 13411 24Angiotech Pharmaceuticals Inc announces financial results for the second quarter ended June 30 2009 13411 25Angiotech Pharmaceuticals Inc announces financial results for the second quarter ended June 30 2009 13411 26Angiotech Pharmaceuticals Inc announces financial results for the second quarter ended June 30 2009 13411 27Angiotech Pharmaceuticals Inc announces financial results for the second quarter ended June 30 2009 13411 28Genomic Health to Present at Canaccord Adams 29th Annual Global Growth Conference 53829 1